Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc
Journal website https://www.thejh.org

Original Article

Volume 12, Number 2, April 2023, pages 66-74

Incidence and Risk of Hematological Adverse Events Associated With Immune Checkpoint Inhibitors: A Systematic Literature Review and Meta-Analysis

Figures

Figure 1.
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram of study selection process.
Figure 2.
Figure 2. Mechanism of action of immune checkpoint inhibitors and hematological complications of immune checkpoint inhibitors. CTLA-4: cytotoxic T lymphocyte antigen-4; MHC: major histocompatibility complex; PD-1: programmed cell death-1 receptor; PD-L1: PD-1 ligand 1; TCR: T-cell receptor.
Figure 3.
Figure 3. The forest plot of the odds ratio of grade I-V hematological adverse events comparing the additional immune checkpoint inhibitor use with control therapy. (a) Anemia. (b) Neutropenia. (c) Thrombocytopenia. CI: confidence interval.